Sanofi
Q2 2022 Earnings Call
Jul 28, 2022, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Eva Schaefer-Jansen
Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi's 2022 second quarter results, followed by a Q&A session. As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to Slide 3.
I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors. With that, please advance to Slide 4. Our speakers on the call today are Paul Hudson, chief executive officer; the global business unit heads, Bill Sibold, Thomas Triomphe, Olivier Charmeil, and Julie Van Ongevalle; and Jean-Baptiste de Chatillon, chief financial officer.
For the Q&A, you have two options to participate: option one, click the raise hand icon at the bottom of your screen; or option two, submit your question by clicking the Q&A icon at the bottom of the screen. And for that, I'd like to turn the call over to Paul.
Paul Hudson -- Chief Executive Officer
Well, thank you, Eva, and thanks to everyone for joining. I'm truly delighted to show our outstanding financial results with you today. And as always, with me here in the room are the key members of the executive team to take you through our business and financial performance. We delivered sales growth of 8.1%, continuing the strong performance we saw in Q1.
Our growth in specialty care has accelerated to more than 21%. Dupixent posted nearly EUR 2 billion in sales and is still growing at a stellar rate above 40%. Our rare disease franchise has grown double digit, driven by legacy products and recent approvals. Continued growth in PPH, further recovery in travel, and booster vaccines drove another strong quarter for our vaccines business.
In general medicines, the focus put on our core assets, well, it continues to pay up. Consumer healthcare delivered another quarter of above-market sales growth, and this speaks volumes about the speed at which our business is transforming into a truly agile, fast-moving, and consumer-centric organization. Moving to Slide 7. Let's take a moment to consider the immense potential of Dupixent.